

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-44. Canceled

45. (Currently amended) A method of treating ~~or preventing~~ clinically manifest mammary tumors, comprising the steps of:

- a) detecting a clinically manifest mammary tumor in a host;
- b) administering to the a host a first dose of hGC; and
- c) administering to the host one or more subsequent doses of hGC, wherein the first dose and the subsequent doses of hCG are administered in an amount and over a period of time having a clinically manifest mammary tumor an amount of hCG effective to inhibit proliferation of mammary tumor cells, thereby treating the clinically manifest mammary tumors.

46-54. Canceled

55. (Previously presented) The method of claim 45, wherein the mammary tumor is a primary tumor.

56. (Previously presented) The method of claim 55, wherein the mammary tumor is a non-invasive carcinoma.

57. (Previously presented) The method of claim 56, wherein the carcinoma is ductal carcinoma *in situ* or lobular carcinoma *in situ*.

58. (Previously presented) The method of claim 45, wherein the mammary tumor is an invasive carcinoma.

59. (Previously presented) The method of claim 58, wherein the carcinoma is tubular or lobular invasive carcinoma.

60. (Previously presented) The method of claim 45, wherein the mammary tumor is a metastatic mammary tumor.

61. (Previously presented) The method of claim 45, wherein the host is a premenopausal woman.

62. (Previously presented) The method of claim 45, wherein the host is a postmenopausal woman.

63. (Currently amended) The method of claim 45, combined with at least one other treatment for clinically manifest mammary tumors ~~cancer therapy~~.

64. (Currently amended) The method of claim 63, wherein the at least one other treatment ~~cancer therapy~~ is surgery or chemotherapy.

65. (Previously presented) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66-69. Canceled

70. (Previously presented) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

71. (Previously presented) The method of claim 45, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

72. (Previously presented) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

73. (Currently amended) The method of claim 45, wherein the one or more subsequent doses of hCG are is administered every second day following administration of the first dose.

74. (Currently amended) The method of claim 45, wherein the one or more subsequent doses of hCG are is administered three times each week following administration of the first dose.

75. (Currently amended) The method of claim 45, wherein the one or more subsequent doses of hCG are is administered for several weeks following administration of the first dose.

76. (Previously presented) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

77. (Previously presented) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (Previously presented) The method of claim 45, wherein the hCG is administered in combination with Type 1 interferon.

79. Canceled.

80. (Previously presented) The method of claim 45, wherein the hCG is recombinant hCG.

81-103. Canceled